Design of the optimal topical system for fluocinonide.
D000085:Acetates; D001702:Biopharmaceutics; D004339:Drug Compounding; D004952:Esters; D005233:Fatty Alcohols; D005446:Fluocinolone Acetonide / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D009824:Ointments; D014677:Pharmaceutical Vehicles; D010919:Placebos; D011409:Propylene Glycols; D012871:Skin Diseases / Q000188:drug therapy; D012995:Solubility; D013329:Structure-Activity Relationship; D014222:Triamcinolone Acetonide; D014662:Vasoconstrictor Agents
D000085:Acetates; D004952:Esters; D005233:Fatty Alcohols; D005938:Glucocorticoids; D009824:Ointments; D014677:Pharmaceutical Vehicles; D010919:Placebos; D011409:Propylene Glycols; D014662:Vasoconstrictor Agents; D005446:Fluocinolone Acetonide; D014222:Triamcinolone Acetonide